Transdermal vs. Oral Estrogen: Which is More Effective?

Hormone doctors serving Chesapeake and Virginia Beach since 2007.

A Synergy Note: Our hormone doctors in Chesapeake have studied extensively with Dr. Neal Rouzier of the Beverly Hills Center for Anti-Aging Medicine, and The Preventive Medicine Clinics in Palm Springs, Calif.    Since 1997, Dr. Rouzier has been a leading expert and authority on bioidentical hormone replacement therapy and anti-aging medicine. Drs. Long and Ryder continue their close relationship with Dr. Rouzier to stay informed on current research and advances in preventive and lifestyle medicine. Following is an important article from Dr. Rouzier’s blog, which you may find helpful.

 

 


Transdermal vs. Oral Estrogen: Which is More Effective?

 

From Dr. Rouzier’s blog – 6/24/2014

While experts agree estrogen has far reaching benefits in menopausal women, researchers tend to disagree on how estrogen therapy should be administered.

Is Transdermal “Less Risky?”

The current trend is to prescribe transdermal estrogen cream. Why do some physicians choose transdermal instead of oral estrogen therapy? Many are worried about the health risks associated with oral estrogen. These concerns were initiated by the Women’s Health Initiative that found oral estrogen increases the risk of myocardial infarction, stroke and blood clots in menopausal women. Therefore, transdermal estrogen is commonly prescribed in lower doses to avoid the damaging atherosclerotic effects of oral conjugated equine estrogen (CEE). Furthermore, it is applied topically and absorbed through the skin. This route of administration bypasses the liver and directly enters the bloodstream to prevent circulatory risks.

What about the benefits of Oral Estrogen?

Transdermal estrogen may seem like a better choice for estrogen hormone therapy, but oral estrogen offers more cardiovascular benefits. In fact, many studies claim transdermal estrogen does not provide any cardiovascular protection. It is estimated that 50-75% of estrogen’s benefits are on LDL and HDL cholesterol, fibrinogen, and fatty acid esters, because oral estrogen passes through the liver to improve cholesterol health. Since transdermal estrogen bypasses the liver to directly enter the bloodstream, it cannot provide advantageous lipid effects. To prevent a large majority of women from succumbing to coronary artery and cardiovascular disease, it is sensible to prescribe an oral estrogen therapy for maximum cardiovascular protection.

Is there is a safer and effective form of oral estrogen.

Hormone doctor Neal Rouzier states that “the medical literature does not support the use of creams and patches over oral bioidentical estrogen. Oral estrogen is far better at protecting women against cardiovascular problems as many studies show a significantly reduced incidence of both heart attacks and strokes with the use of oral as compared to the use of transdermal estrogen creams or patches. Transdermal estrogen has only a minimal effect on improving blood lipids (good and bad cholesterol and blood fats) — whereas oral estrogen has a much stronger value in doing this. Many medical studies on hormone therapy have demonstrated that oral estrogen’s effect on total cholesterol, LDL and HDL-cholesterol provide greater overall protection, whereas transdermal provides much less protection and therefore they provide less cardiovascular protection in the long run. The patch and transdermal creams are not entirely without value. There are a few women with certain types health histories, where oral estrogen is contraindicated and transdermal estrogen replacement may be appropriately recommended. However, this is not the case for the great majority of women. Oral estrogen have many more health protective benefits than does transdermal estrogen and therefore the preferred form of estrogen.”

When it comes to oral estrogen, medical studies, hormone doctors, and lifestyle medicine practitioners have found that oral e2 estradiol is the safest and most effective form, because it avoids inherent side effects related to oral CEE. The Women’s Estrogen for Stroke Trial (WEST) found oral estradiol was not associated with increased blood clots, but an increase in blood vessel inflammation and clotting was due to ten biologically active estrogens that are in CEE (Premarin). These active estrogens are not found in estradiol.

Conclusion

Prescribing the right form of estrogen during hormone therapy should be considered on an individual basis. Older women (age>60) that have never taken oral estrogen are advised to take transdermal estrogen to avoid the risk of myocardial infarction or stroke. Additionally, transdermal estrogen is the best choice for women that have a history of clotting disorders. For women that do not have these established factors, oral estradiol is the best choice for protecting the heart from cardiovascular disease and hypertension risks that increase dramatically in menopausal women.